Tamoxifen citrate AC SGK3 degrader-1 InChi: InChI=1S/C46H47ClN10O8S/c1-24-25(2)66-46-40(24)41(27-11-13-28(47)14-12-27)50-33(43-55-52-26(3)57(43)46)21-38(59)48-17-6-7-18-49-39(60)23-65-42-35(63-4)19-29(20-36(42)64-5)53-54-32-10-8-9-30-31(32)22-56(45(30)62)34-15-16-37(58)51-44(34)61/h8-14

InChi: InChI=1S/C46H47ClN10O8S/c1-24-25(2)66-46-40(24)41(27-11-13-28(47)14-12-27)50-33(43-55-52-26(3)57(43)46)21-38(59)48-17-6-7-18-49-39(60)23-65-42-35(63-4)19-29(20-36(42)64-5)53-54-32-10-8-9-30-31(32)22-56(45(30)62)34-15-16-37(58)51-44(34)61/h8-14

Smiles: CN1CCN(CC1)C1C=CC(=CC=1)NC1=NC2=C(C=N1)C(=O)N(CC=C)N2C1=CC=CC(=N1)C(C)(C)O

Chemical Name: 2-chloro-5-[2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl]phenol

de Haven Brandon AK

Solubility: DMSO : ≥ 46 mg/mL (106

Tamoxifen citrate AC SGK3 degrader-1 InChi: InChI=1S/C46H47ClN10O8S/c1-24-25(2)66-46-40(24)41(27-11-13-28(47)14-12-27)50-33(43-55-52-26(3)57(43)46)21-38(59)48-17-6-7-18-49-39(60)23-65-42-35(63-4)19-29(20-36(42)64-5)53-54-32-10-8-9-30-31(32)22-56(45(30)62)34-15-16-37(58)51-44(34)61/h8-14Tamoxifen, also known as ICI 46474, is an antagonist of the estrogen receptor in breast tissue via its active metabolite, 4 hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a selective estrogen receptor modulator. Tamoxifen is the usual endocrine (anti estrogen) therapy for hormone receptor positive breast cancer in pre menopausal women, and is also a standard in post menopausal